fluconazole has been researched along with Atrial Fibrillation in 4 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
Excerpt | Relevance | Reference |
---|---|---|
"Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance and several reports suggesting associations." | 8.12 | Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. ( Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C, 2022) |
"Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance and several reports suggesting associations." | 4.12 | Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. ( Blanche, P; Gislason, GH; Hansen, ML; Holt, A; Jensen, MH; Lamberts, M; McGettigan, P; Nouhravesh, N; Rasmussen, PV; Schjerning, AM; Schou, M; Strange, JE; Torp-Pedersen, C, 2022) |
" When FE is complicated with prosthetic heart valve and/or atrial fibrillation, the coadministration of antifungal agents and warfarin is inevitable." | 3.96 | Fungal endocarditis with heart valve replacement and atrial fibrillation posing a treatment challenge: A case report. ( Cao, S; Ding, C; Wang, R; Xia, M; Zhu, X, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (75.00) | 2.80 |
Authors | Studies |
---|---|
Holt, A | 1 |
Strange, JE | 1 |
Rasmussen, PV | 1 |
Blanche, P | 1 |
Nouhravesh, N | 1 |
Jensen, MH | 1 |
Schjerning, AM | 1 |
Schou, M | 1 |
Torp-Pedersen, C | 1 |
Gislason, GH | 1 |
Hansen, ML | 1 |
McGettigan, P | 1 |
Lamberts, M | 1 |
Shimoda, T | 1 |
Watanabe, A | 1 |
Zhu, X | 1 |
Cao, S | 1 |
Xia, M | 1 |
Ding, C | 1 |
Wang, R | 1 |
Shibata, S | 1 |
Kami, M | 1 |
Kanda, Y | 1 |
Machida, U | 1 |
Iwata, H | 1 |
Kishi, Y | 1 |
Takeshita, A | 1 |
Miyakoshi, S | 1 |
Ueyama, J | 1 |
Morinaga, S | 1 |
Mutou, Y | 1 |
4 other studies available for fluconazole and Atrial Fibrillation
Article | Year |
---|---|
Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azoles; Cross-Over Studies; Dabigatran | 2022 |
Apixaban for Atrial Fibrillation and Systemic Fluconazole: Bleeding Risk and Possible Preventative Measures.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Fluconazole; Hemorrhage; Humans; Pyrazole | 2022 |
Fungal endocarditis with heart valve replacement and atrial fibrillation posing a treatment challenge: A case report.
Topics: Antifungal Agents; Atrial Fibrillation; Candida parapsilosis; Candidiasis; Caspofungin; Combined Mod | 2020 |
Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Antibiotic Prophylaxis; Antifungal Agents; Antin | 2001 |